Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vical To Retain Marketing Rights To Allovection-7 In Deal With AnGes

This article was originally published in The Pink Sheet Daily

Executive Summary

AnGes gains Japanese rights to the cancer biologic as part of the $100 mil. agreement.

You may also be interested in...



Vical Shifts To Infectious Disease After Allovectin Fails In Melanoma

CEO Vijay Samant defends Vical’s DNA-based technology platform after 20 years of development culminates in Phase III failure. But the platform still shows promise in other therapeutic areas, Vical says as the company absorbs a major blow to stock price.

Cash-Strong Vical Narrows Focus To Two Lead Programs

Wary of current financial environment, biotech is bullish on early pipeline projects but will await partners to advance them.

Cash-Strong Vical Narrows Focus To Two Lead Programs

Wary of current financial environment, biotech is bullish on early pipeline projects but will await partners to advance them.

Related Content

Topics

UsernamePublicRestriction

Register

PS064250

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel